These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8493562)

  • 1. Another reversal for the AIDS Vaccine Trial?
    Science; 1993 May; 260(5112):1227. PubMed ID: 8493562
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
    DePalma L
    Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
    [No Abstract]   [Full Text] [Related]  

  • 3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 4. MicroGeneSys drops out of NIH trial for AIDS vaccine.
    Macilwain C
    Nature; 1993 Mar; 362(6418):277. PubMed ID: 8455703
    [No Abstract]   [Full Text] [Related]  

  • 5. Trial results thwart HIV-vaccine hopes.
    McCarthy M
    Lancet; 1996 Apr; 347(9009):1173. PubMed ID: 8609757
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model.
    Mosier DE; Gulizia RJ; MacIsaac P; Mathieson BJ; Smith G; Hu SL; Corey L; Greenberg P
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1387. PubMed ID: 1466962
    [No Abstract]   [Full Text] [Related]  

  • 7. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
    Graham BS
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Patel GB; Newman FK; Mandava M; Belshe RB
    Vaccine; 1995 Sep; 13(13):1170-9. PubMed ID: 8578800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HHS fumbles ball on AIDS vaccine trial.
    Science; 1993 Jul; 261(5118):151. PubMed ID: 8327883
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccine compromise.
    Nature; 1993 Apr; 362(6421):576. PubMed ID: 8464502
    [No Abstract]   [Full Text] [Related]  

  • 13. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.
    Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE
    J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet antibodies during the course of HIV-preventive vaccine trial.
    Kaplan C; Morel-Kopp MC; Kieny MP; Kolbe H; Salmon P; Sicard D; Pialoux G; Meignier B; Excler JL; Plotkin S
    AIDS; 1996 Apr; 10(4):447-9. PubMed ID: 8728055
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 16. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.
    Barrett N; Eder G; Dorner F
    Biotechnol Ther; 1991; 2(1-2):91-106. PubMed ID: 1845126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Army to test only MicroGeneSys vaccine.
    Science; 1993 Aug; 261(5123):819. PubMed ID: 8346429
    [No Abstract]   [Full Text] [Related]  

  • 20. The prospects for AIDS vaccines.
    Koff WC
    Hosp Pract (Off Ed); 1991 Apr; 26(4):99-106. PubMed ID: 2010483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.